Finn
KRYS Biotechnology · Gene therapy · Commercial-stage · Rare disease · Thesis updated November 8, 2026

VYJUVEK cash funds buybacks and a wider gene therapy platform

01 Running thesis

From one product to a platform

Krystal is still a VYJUVEK story today. The company reported $127.3 million of Q3 2026 net product revenue, and all of it came from that one product. That concentration is real, but the launch is scaling outside the US, aided by the successful conclusion of pricing negotiations in Germany and Italy.

The bull case is that VYJUVEK can fund the next wave and return capital to shareholders. The company authorized a $400 million share repurchase program while advancing its expansive pipeline. Krystal owns its HSV-1 gene delivery platform, its manufacturing, and its worldwide rights. The oncology pipeline recently showed a bright spot with KB113 demonstrating profound clearance in a Gorlin syndrome pilot study.

The bear case centers on timing and clinical execution. Management pushed several key pipeline milestones into 2027, including top-line results for KB803 in ocular DEB and KB801 in neurotrophic keratitis. Slow enrollment and patient dropouts highlight the difficulty of running rare disease trials. If VYJUVEK growth slows before another product is approved, the stock may have less room for error.

Nov 2026▲Q3 2026 revenue reached $127.3 million. The board authorized a $400 million share repurchase program, and German and Italian pricing concluded. However, key clinical readouts for KB803 and KB801 were pushed to 2027.
Aug 2026▲Q2 2026 revenue reached $119.2 million, with US growth offset by flat sequential EU revenue due to German pricing accruals. VYJUVEK secured UK MHRA approval, and the oncology pipeline expanded with KB707 in Gorlin syndrome.
May 2026▲Q1 2026 showed $116.4 million of VYJUVEK revenue and clarified the mix, with $87.5 million from the US and $28.9 million from Europe plus Japan. FDA platform technology designations for KB407, KB111, and KB801 strengthened the platform case, while US maintenance dosing added revenue lumpiness.
Feb 2026▲The FY 2025 10-K showed $389.1 million of full-year VYJUVEK revenue and more than $827 million of year-end cash. The thesis moved further from single-product launch story toward platform story, helped by KB407 lung delivery data and KB707 regulatory progress.
Nov 2025▲Krystal became a more global commercial company after VYJUVEK launches in Germany, France, and Japan. Quarterly revenue reached $97.8 million, and FDA platform designation for KB801 added platform support.
Aug 2025▲Japan approved VYJUVEK in July 2025, adding to the European approval and reducing global launch risk. Q2 2025 revenue of $96.0 million showed continued US strength.
May 2025▲Q1 2025 revenue reached $88.2 million, and the European Commission approved VYJUVEK in April 2025. KB803 also moved toward a registrational Phase 3 study.
Feb 2025▲FY 2024 confirmed a strong first full year for VYJUVEK, with $290.5 million of revenue. Pipeline updates in oncology and respiratory programs gave early evidence that the platform could work beyond the lead skin product.
02 Business model

A gene therapy gel business

Krystal makes money by selling genetic medicines. Its only commercial product is VYJUVEK, a topical gel for dystrophic epidermolysis bullosa, or DEB. DEB is a rare disease where skin can blister and wound easily because the body lacks working collagen VII.

VYJUVEK is important because it is redosable. Many gene therapies are one-time treatments, but VYJUVEK can be applied again to wounds. That gives Krystal a recurring treatment model, not just a one-shot sale.

The company is vertically integrated, which means it runs the chain from research through manufacturing and commercialization. That can help in gene therapy, where making the product is hard. It also means a plant problem could hit supply, clinical trials, and launches at the same time.

Krystal owns exclusive worldwide rights to its products. This keeps more economics in-house, but it also puts more work on the company as it expands in Europe, Japan, and the UK.

03 Product portfolio

One seller, many shots

Cash cow

VYJUVEK

VYJUVEK is the sole commercial product. It is approved in the US, Europe, Japan, and the UK for DEB and produced all $127.3 million of Q3 2026 net product revenue.

Growth engine

KB803

KB803 is an eye drop form of VYJUVEK for ocular DEB. The Phase 3 study added patients to ensure statistical strength, pushing top-line results to early 2027.

Option

KB407

KB407 is an inhaled gene therapy for cystic fibrosis. Krystal is running a repeat-dose safety study, with interim results expected in the first half of 2027.

Option

KB801

KB801 targets neurotrophic keratitis. Enrollment has been slow due to a competing commercial alternative, pushing top-line data into 2027.

Option

KB113 and KB707

KB113 showed profound responses in a Gorlin syndrome pilot study. KB707 is enrolling a larger Phase I/II expansion cohort in non-small cell lung cancer.

Option

KB408 and KB111

KB408 targets alpha-1 antitrypsin deficiency, while KB111 targets Hailey-Hailey disease. Both test whether the HSV-1 platform can work beyond skin wounds.

Option

KB304

KB304 sits inside the Jeune Aesthetics subsidiary and targets wrinkles. A Phase 2 study is expected to start in 2027.

04 Business segments

VYJUVEK is the business today

US VYJUVEK75%modest
Europe and Japan VYJUVEK25%modest

Krystal reports one operating segment. For Q3 2026, global revenue was $127.3 million, all from VYJUVEK. The US contributed $95.3 million, while international markets added $32.0 million.

05 Risk factors

What could break the thesis

One-product dependence

High impact · High odds

Krystal's commercial revenue still comes from VYJUVEK. If demand slows, payer access tightens, or patient use drops, the pipeline may not be ready to replace that growth. This matters most before KB803 or another program can become a second approved product.

We watchTrack quarterly VYJUVEK net product revenue and any sign of slowing growth before the KB803 readout.

Maintenance dosing lumpiness

Medium impact · Medium odds

Management has noted that US revenue is affected by patients moving into a start-stop maintenance cadence. Some patients may not need steady treatment every quarter. The disease burden has not changed, but revenue timing could get harder to predict.

We watchWatch US VYJUVEK revenue each quarter and management comments on patient adherence and restart rates.

Pipeline delay or failure

High impact · High odds

The platform story depends on more than VYJUVEK. KB803, KB801, and KB407 all experienced timeline delays into 2027 due to enrollment and dropout issues. Further delays or a trial failure could hurt confidence in the wider platform.

We watchWatch KB803 top-line data in early 2027 and whether KB801 can successfully accelerate enrollment.

International execution risk

Medium impact · Medium odds

While German and Italian pricing negotiations have concluded, Krystal still must execute on launching and navigating other global markets like Spain and France. Weak adoption or access issues could lower the long-term value of those regions.

We watchWatch international revenue growth in early 2027 and the pricing decision in Spain expected in late 2026.

Manufacturing disruption

High impact · Low odds

Krystal makes complex biologic products in-house. That control is a strength when things run well. A quality issue, delay, or capacity problem could hurt VYJUVEK supply and slow clinical trials.

We watchWatch for FDA inspection findings, product supply comments, or delays tied to CGMP manufacturing.

Drug pricing politics

Medium impact · Medium odds

Krystal sells high-cost genetic medicines, so pricing policy matters. Executive orders and proposed legislation on drug pricing reform create uncertainty. Even without a new law, payer pressure can change access and net price.

We watchWatch US drug pricing proposals and any change in payer coverage for VYJUVEK.
06 Quick answers

In one breath

What does Krystal Biotech actually sell?

Krystal sells VYJUVEK, a topical redosable gene therapy gel for DEB wounds. In Q3 2026, all $127.3 million of net product revenue came from VYJUVEK.

Why is the HSV-1 platform important?

Krystal uses an engineered herpes simplex virus-1, or HSV-1, to deliver genes into cells. FDA platform technology designations suggest the agency may let Krystal reuse parts of its platform data across programs.

What is the next big catalyst for KRYS?

The clearest near-term catalysts are top-line data from the Phase 3 study of KB803 in ocular DEB in early 2027, and data updates from the KB105 study before year-end 2026.

What is the main risk for KRYS stock?

The main risk is that Krystal still depends on one commercial product. Pipeline readouts have been pushed to 2027, meaning the company relies heavily on VYJUVEK revenue holding steady.

07 Research standards

Sources and research notes

This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.

Thesis reviewed
November 8, 2026
Score data
November 15, 2026
Reviewed by
Shivam Bharuka
  1. Krystal Biotech Q3 2026 earnings transcript
  2. Krystal Biotech Q2 2026 Form 10-Q
08 Explore the industry

Comparable Biotechnology companies

Companies near Krystal Biotech, Inc. in Finn's Biotechnology industry ranking.

Get started with Finn today